Exabis Library
Welcome to the e-CCO Library!
P361: Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P361: No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P361: Patterns of use and durability of initial and sequential biological agents in a large Paediatric inflammatory bowel disease observational cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P361: PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P361: Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P362: Anti-virus treatment against CMV in patients with ulcerative colitis by the PCR monitoring for mucosal CMV-DNA
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P362: Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P362: Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P362: Magnetic resonance healing predicts long-term outcomes in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P362: Six-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P362: Systematic review: Oncological outcomes of patients with Inflammatory Bowel Disease undergoing segmental colonic resections for colorectal cancer and dysplasia
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P363 Moderate endurance and muscle training are safe to perform for patients with quiescent or mild active Crohn’s disease and increases their strength
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P363: Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P363: Depression and anxiety in Clostridioides difficile infection compared with inflammatory bowel disease during the Covid-19 pandemic
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P363: Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P363: Efficacy and safety of golimumab in patients with ulcerative colitis: a prospective multicentre study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P363: Locally injected allogeneic bone marrow-derived mesenchymal stromal cells for the treatment of refractory proctitis: clinical results of a phase IIa trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P363: The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM